Novel antibiotics named kigamicin A, B, C, D, and E were discovered from the culture broth of Amycolatopsis sp. ML630-mF1 by their selective killing activity against PANC-1 cells only under a nutrient starved condition. Under a condition of nutrient starvation, kigamicins A, B, C, and D inhibited PANC-1 cell survival at 100 times lower concentration than in normal culture. Kigamicins showed antimicrobial activity against Gram-positive bacteria including methicillin resistant Staphylococcus aureus (MRSA). Kigamicin D inhibited the growth of various mouse tumor cell lines at IC50 of about 1 microg/ml.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.7164/antibiotics.56.1004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Induction of necrosis in human myeloma cells by kigamicin.
Anticancer Res
April 2008
Department of Hematology, Kumamoto University Hospital, Kumamoto, Japan.
Background: Kigamicin (KGM) is a novel compound derived from Actinomycetes that was originally reported to induce necrosis in pancreatic cancer cells only under nutrient-starved conditions via inhibition of PI3-kinase. The effects of KGM on myeloma cells were investigated.
Materials And Methods: Cytotoxic activity was quantified using WST8 assay.
Amycolatopsis regifaucium sp. nov., a novel actinomycete that produces kigamicins.
Int J Syst Evol Microbiol
November 2007
School of Biology, University of Newcastle, Newcastle upon Tyne NE1 7RU, UK.
The taxonomic position of seven soil actinomycetes provisionally assigned to the genus Amycolatopsis was established in a polyphasic study. The isolates, which had identical 16S rRNA gene sequences, had closest similarity to the type strain of Amycolatopsis orientalis. A representative isolate, strain GY080T, had chemotaxonomic properties that were typical of the genus Amycolatopsis and could be distinguished from the type strain of A.
View Article and Find Full Text PDFAntitumor effect of kigamicin D on mouse tumor models.
J Antibiot (Tokyo)
April 2006
Numazu Bio-Medical Research Institute, Microbial Chemistry Research Center, 18-24 Miyamoto, Numazu-shi, Shizuoka 410-0301, Japan.
Kigamicin D is a novel anticancer agent that was identified using a new screening strategy that targets the tolerance of cancer cells to nutrient starvation [1, 2]. Oral administration of kigamicin D was previously described to show a strong antitumor effect in human tumor xenograft models of pancreatic tumors [2]. In this paper we describe that kigamicin D shows the same selective cytotoxicity against normal human cells such as lung fibroblast and prostate stromal cells under nutrient starved condition as against cancer cells.
View Article and Find Full Text PDFKigamicin D, a novel anticancer agent based on a new anti-austerity strategy targeting cancer cells' tolerance to nutrient starvation.
Cancer Sci
June 2004
Investigative Treatment Division, National Cancer Center Research Institute East, Chiba 277-8577, Japan.
Both tolerance to nutrient starvation and angiogenesis are essential for cancer progression because of the insufficient supply of nutrients to tumor tissue. Since chronic nutrient starvation seldom occurs in normal tissue, cancer's tolerance to nutrient starvation should provide a novel target for cancer therapy. In this study, we propose an anti-austerity strategy to exploit the ability of agents to eliminate cancer cells' tolerance to nutrient starvation.
View Article and Find Full Text PDFKigamicins, novel antitumor antibiotics. II. Structure determination.
J Antibiot (Tokyo)
December 2003
Microbial Chemistry Research Center, Numazu Bio-Medical Research Institute, 18-24 Miyamoto, Numazu-shi, Shizuoka 410-0301, Japan.
Kigamicin A (1), B (2), C (3), D (4) and E (5) are novel antitumor antibiotics. Their structures were determined by spectroscopic analyses including various NMR measurements. Kigamicins have a unique aglycone of fused octacyclic ring system containing seven of six-membered rings and one oxazolidine.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!